Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
Abstract Immunotherapy is an expanding area of cancer treatment with significant promise. Despite their efficacy, checkpoint inhibitors are associated with a number of immune‐related adverse events; here, we described thrombocytopenia secondary todurvalumab.
Main Authors: | Sean C. Dougherty, Alia C. Lynch, Richard D. Hall |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-06-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.4227 |
Similar Items
-
Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)
by: Anne Zufferey, et al.
Published: (2017-02-01) -
Successful treatment with eltrombopag in avoiding splenectomy for patients with chronic refractory immune thrombocytopenia
by: Alhossain A. Khalafallah, et al.
Published: (2012-01-01) -
Secondary Immune Thrombocytopenia (ITP) Associated with ChAdOx1 Covid-19 Vaccination – A Case Report
by: Martin Koch, et al.
Published: (2021-07-01) -
Improved Mouse Models for the Study of Treatment Modalities using Sulfur-containing Small-molecular-Weight Molecules for Passive Immune-mediated Thrombocytopenia
by: Katsman, Yulia
Published: (2009) -
Improved Mouse Models for the Study of Treatment Modalities using Sulfur-containing Small-molecular-Weight Molecules for Passive Immune-mediated Thrombocytopenia
by: Katsman, Yulia
Published: (2009)